Opening GPAtlas…

🌊 The Ocean Library · GP clinical topic

Inhaled Corticosteroids

Written and reviewed by practising UK GPs, overseen by our Clinical Advisory Officer.

🧭 When to suspect

Inhaled corticosteroids (ICS) are the cornerstone anti-inflammatory treatment in asthma and are used selectively in chronic obstructive pulmonary disease (COPD). At the low-to-medium doses taken by most patients they are safe and highly effective, and their benefits – fewer exacerbations and fewer asthma deaths – far outweigh their risks. Suspect an ICS-related problem when a patient develops local side effects (hoarseness, oral thrush) or features of systemic absorption, particularly on high doses long-term, on a potent agent (fluticasone), or when an interacting drug has been started.

Two practical skills matter in primary care: recognise and treat the common, benign local effects (largely prevented by a spacer and mouth-rinsing), and stay alert to the uncommon but serious systemic effects of high-dose therapy – chiefly hypothalamic–pituitary–adrenal (HPA) axis suppression. The unifying principle throughout is to prescribe the lowest effective dose.

Local effects (common, dose-related) Systemic effects (uncommon, high-dose / long-term)

Oral candidiasis (thrush) – the commonest, affecting roughly 1 in 30 users

Dysphonia / hoarseness – often a laryngeal myopathy rather than thrush

Throat irritation, cough, reflex bronchospasm on inhalation

Paradoxical bronchospasm – rare but potentially severe

Adrenal (HPA-axis) suppression → risk of adrenal crisis under stress

Reduced bone mineral density / fracture – modest and dose-dependent

Cataract and glaucoma; rarely central serous chorioretinopathy

Skin thinning, easy bruising, purpura

Reduced growth velocity in children (small, largely non-progressive)

Increased pneumonia risk in COPD; rarely Cushingoid features, hyperglycaemia, mood change

Risk rises with dose and duration, and is greatest with fluticasone, in children, in the elderly, and when an ICS is combined with a potent CYP3A4 inhibitor. Systemic effects are unusual below a beclometasone-equivalent dose of around 800–1000 micrograms/day.

Source: NICE NG245 · NICE NG115 · MHRA


🔒 Sign up free to read the full topic

You're viewing a free preview. Create a free account to unlock the rest.

Sign up free →
Inside the full topic 🔒 History🔒 Red Flags🔒 Examination🔒 Patient Explanation🔒 Investigations🔒 Management🔒 Non-pharmacological Treatment🔒 Pharmacological Treatment🔒 Special Notes🔒 Referral Pathways🔒 Take Home Messages

Sample topics are open to everyone in the Free Sample Bundle.

Part of The Ocean Library, 450+ structured clinical topics mapped to the primary care curriculum. Companion audio in Echo · one-page summary in The Scope.

We use cookies to enhance your browsing experience, provide personalised content, and analyse our traffic. By clicking "Accept All", you consent to our use of cookies. Privacy policy